SG11202109857UA - Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia - Google Patents
Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemiaInfo
- Publication number
- SG11202109857UA SG11202109857UA SG11202109857UA SG11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- formula
- hydrogen atom
- independently selected
- bfu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823214P | 2019-03-25 | 2019-03-25 | |
| PCT/US2020/023989 WO2020198054A1 (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109857UA true SG11202109857UA (en) | 2021-10-28 |
Family
ID=72608578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109857U SG11202109857UA (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12497411B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3946321A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7558187B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102914803B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113613650B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020247812B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021019189A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132381A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286617A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011588A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109857UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020198054A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3649626A (en) * | 1970-04-27 | 1972-03-14 | Warner Lambert Co | Fused ring systems containing (1 3)oxazine |
| DK1282625T3 (da) * | 2000-05-09 | 2004-11-15 | Warner Lambert Co | Anvendelsen af benzoxaziner i behandlingen af Parkinsons sygdom |
| CA2357306A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Fused ring system containing indole as m4 selective aza-anthracene muscarinic receptor antagonists |
| US8329689B2 (en) * | 2006-05-23 | 2012-12-11 | Alexandre Vasilievich Ivachtchenko | Substituted indoles and a method for the production and use thereof |
| US20130059783A1 (en) * | 2010-03-12 | 2013-03-07 | Johan Flygare | Compositions and methods for expanding bfu-e cells |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
-
2020
- 2020-03-20 CN CN202080024089.9A patent/CN113613650B/zh active Active
- 2020-03-20 JP JP2021553300A patent/JP7558187B2/ja active Active
- 2020-03-20 AU AU2020247812A patent/AU2020247812B2/en active Active
- 2020-03-20 CA CA3132381A patent/CA3132381A1/en active Pending
- 2020-03-20 KR KR1020217029823A patent/KR102914803B1/ko active Active
- 2020-03-20 SG SG11202109857U patent/SG11202109857UA/en unknown
- 2020-03-20 EP EP20776829.2A patent/EP3946321A4/en active Pending
- 2020-03-20 WO PCT/US2020/023989 patent/WO2020198054A1/en not_active Ceased
- 2020-03-20 MX MX2021011588A patent/MX2021011588A/es unknown
- 2020-03-20 BR BR112021019189A patent/BR112021019189A2/pt unknown
- 2020-03-20 US US17/442,926 patent/US12497411B2/en active Active
-
2021
- 2021-09-23 IL IL286617A patent/IL286617A/en unknown
-
2024
- 2024-05-20 JP JP2024081788A patent/JP2024102364A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL286617A (en) | 2021-10-31 |
| KR102914803B1 (ko) | 2026-01-20 |
| CA3132381A1 (en) | 2020-10-01 |
| EP3946321A4 (en) | 2023-03-08 |
| JP2024102364A (ja) | 2024-07-30 |
| JP2022525293A (ja) | 2022-05-12 |
| MX2021011588A (es) | 2021-12-15 |
| CN113613650B (zh) | 2024-12-10 |
| AU2020247812B2 (en) | 2025-09-11 |
| BR112021019189A2 (pt) | 2021-11-30 |
| KR20210144697A (ko) | 2021-11-30 |
| AU2020247812A1 (en) | 2021-09-30 |
| JP7558187B2 (ja) | 2024-09-30 |
| US20220185821A1 (en) | 2022-06-16 |
| CN113613650A (zh) | 2021-11-05 |
| WO2020198054A1 (en) | 2020-10-01 |
| EP3946321A1 (en) | 2022-02-09 |
| US12497411B2 (en) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3230542A1 (en) | Novel ras inhibitors | |
| EP2822952B1 (en) | Aryl ether-base kinase inhibitors | |
| EP2880032B1 (en) | Aryl lactam kinase inhibitors | |
| RS54038B1 (sr) | Imidazo[4,5-c]hinolini kao inhibitori dnk-pk | |
| KR20190003750A (ko) | 암을 치료하기 위한 1-테트라히드로피라닐카르보닐-2,3-디히드로-1h-인돌 화합물 | |
| JP2022504541A (ja) | 低分子ｍｄｍ２タンパク質デグレーダー | |
| AU2018309739B2 (en) | Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia | |
| EP3099300B1 (en) | Aryl lactam kinase inhibitors | |
| KR102583817B1 (ko) | 피롤로[1,2-b]피리다진 유도체 | |
| WO2020076738A2 (en) | Protein-binding compounds | |
| EP3108883A1 (en) | Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway | |
| JP2022522942A (ja) | 有機化合物 | |
| JP2024102364A (ja) | 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト | |
| KR102184069B1 (ko) | 디히드로-피리도-옥사진 유도체의 고체 형태 | |
| US12458637B2 (en) | Targeting WNK1 in blood cancers | |
| JP2019509316A (ja) | ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体 | |
| JP6310474B2 (ja) | ジヒドロ−ピリド−オキサジン誘導体の固体形態 | |
| JP2004505094A (ja) | 免疫調節化合物 | |
| CN116162093A (zh) | 一种tyk2抑制剂化合物及其用途 |